Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07040072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Study acronym: LONG'E
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Jun 2025 to Oct 9, 2025
    • Eligibility criteria shortened, about 30 words
    • Study description revised
    • Site details revised
    • Collaborators reordered
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent/metastatic HNSCC patients.
Trial Details
NCT Number NCT07040072
Lead Sponsor Beijing Tongren Hospital
Collaborators: Sinocelltech Ltd., Keymed Biosciences Co.Ltd
Conditions
(from sponsor)		 HNSCC
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov